321 related articles for article (PubMed ID: 33257454)
1. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection.
Kawaguchi N; Katsube T; Echols R; Wajima T
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257454
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.
Kawaguchi N; Katsube T; Echols R; Wajima T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29038272
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
4. Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects.
Kawaguchi N; Katsube T; Echols R; Wajima T; Nicolau DP
J Clin Pharmacol; 2022 May; 62(5):670-680. PubMed ID: 34648652
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.
Katsube T; Wajima T; Ishibashi T; Arjona Ferreira JC; Echols R
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795374
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin.
Katsube T; Echols R; Wajima T
Clin Infect Dis; 2019 Nov; 69(Suppl 7):S552-S558. PubMed ID: 31724042
[TBL] [Abstract][Full Text] [Related]
9.
Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
[TBL] [Abstract][Full Text] [Related]
10. Cefiderocol: A Siderophore Cephalosporin.
El-Lababidi RM; Rizk JG
Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
[TBL] [Abstract][Full Text] [Related]
11. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
Gatti M; Bartoletti M; Cojutti PG; Gaibani P; Conti M; Giannella M; Viale P; Pea F
J Glob Antimicrob Resist; 2021 Dec; 27():294-298. PubMed ID: 34710630
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
13. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
Syed YY
Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol to treat complicated urinary tract infection.
McCarthy MW
Drugs Today (Barc); 2020 Mar; 56(3):177-184. PubMed ID: 32282864
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.
Bilal M; El Tabei L; Büsker S; Krauss C; Fuhr U; Taubert M
Clin Pharmacokinet; 2021 Dec; 60(12):1495-1508. PubMed ID: 34420182
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.
Matsumoto S; Singley CM; Hoover J; Nakamura R; Echols R; Rittenhouse S; Tsuji M; Yamano Y
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630178
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S
Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
[TBL] [Abstract][Full Text] [Related]
19. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
[TBL] [Abstract][Full Text] [Related]
20. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
